Tech Company Inital Public Offerings
Kinnate Biopharma IPO
Based in San Diego, Kinnate Biopharma is now a public company.
Transaction Overview
Company Name
Announced On
12/2/2020
Transaction Type
IPO
Amount
$240,000,000
Proceeds Purpose
Per the firm's most recent regulatory filing, it plans to use the net proceeds as follows:approximately $105.0 million to fund the continued development of our RAF program, including our most advanced product candidate, KIN002787;approximately $35.0 million to fund the continued development of product candidates in our FGFR program; andthe remaining amounts, if any, to fund the continued development of our other research programs, as well as for working capital and other general corporate purposes.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
11975 El Camino Real 101
San Diego, CA 92130
USA
San Diego, CA 92130
USA
Phone
Website
Email Address
Not Recorded
Overview
Kinnate Biopharma (Nasdaq: KNTE) is a biopharmaceutical company advancing a pipeline of precision oncology therapeutics to treat patients with genomically defined vulnerabilities.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 12/2/2020: Infogrid venture capital transaction
Next: 12/2/2020: Tallac Therapeutics venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on all VC transactions involving tech companies. All VC database entries reported here are derived from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs